InhaleRx locks in A$1m cap raise and reveals plans to rebrand by Adam Sheldon December 1, 2025December 2, 2025 InhaleRx has received commitments to raise $750,000 through a placement and announced plans for a $250,000 […]
Financial news in brief: Elixinol addresses funding concerns; Aurora growth helped by Australia; Avecho lifts cash, progresses trial; Cann receives NAB extension to finalise settlement; IRX reports lean quarter by Adam Sheldon November 4, 2025November 6, 2025
News in brief: Cann Group trading halt; Avecho raises $2.5m for CBD submission; IRX CEO takes shares over salary by Adam Sheldon October 23, 2025October 23, 2025
News in brief: Losses widen for Avecho and Elixinol; InhaleRx secures HREC approval; Zelira cuts deficit; Argent shifts from ‘non-core’ activities by Adam Sheldon August 29, 2025September 4, 2025
InhaleRx reports half-year loss but advances clinical trial plans by Martin Lane August 26, 2025August 28, 2025
News in brief: Elixinol names new CEO; Aurora flags MedReleaf growth; InhaleRx R&D tax rebate; ODC to ‘share insights’; Tilray appoints new Australian director by Steve Jones June 20, 2025June 26, 2025
News in brief: Tilray launches pastilles; InhaleRx progresses panic disorder trial; NSW calls for hemp plan feedback; BS3 makes key hire by Steve Jones and Martin Lane April 23, 2025April 23, 2025
InhaleRx eyes big pharma deal and ponders product launch through SAS by Steve Jones March 18, 2025March 18, 2025
InhaleRx prepares for pivotal trial in quest to provide relief from breakthrough cancer pain by cannabiz team January 29, 2025January 31, 2025
